Relay Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Relay Therapeutics, Inc. (RLAY), a biopharmaceutical company based in Cambridge, Massachusetts, filed this Current Report on Form 8-K on August 8, 2023. The filing announces the financial results for the quarter ended June 30, 2023, and includes an updated corporate presentation.
Key Financial Metrics
The provided text serves as a cover document referencing a press release (Exhibit 99.1) and a corporate presentation (Exhibit 99.2). The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached exhibits for detailed financial data.
Material Changes
No specific material changes in financial performance or operational status are detailed within the body of this Form 8-K. The document solely confirms the release of Q2 2023 results and an updated corporate presentation.
Guidance, Outlook, and Risks
The filing references an updated corporate presentation which may contain management commentary, outlook, and risk factors, but the specific content of these items is not included in the text of the Form 8-K. The filing explicitly states that the information in the exhibits is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2023 revenue, net loss, and cash position figures.
- Examine Exhibit 99.2 (Corporate Presentation) for updated clinical trial timelines, pipeline progress, and forward-looking guidance.
- Verify the company's cash runway and burn rate as disclosed in the full financial statements referenced in the press release.
- Check for any new risk factors or contingencies disclosed in the attached presentation that were not present in prior filings.